Grundlæggende statistik
| CIK | 890846 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Uroplasty Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| April 1, 2015 |
CGNT / Cogentix Medical, Inc. / Uroplasty Inc - SC 13D/A Activist Investment SC 13D/A 1 s000823x11sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Cogentix Medical, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 19243A104 (CUSIP Number) Brett Reynolds Chief Financial Officer and Corporate Secretary Uroplasty, LLC (f/k/a Uro |
|
| March 3, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2015 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 3, 2015 |
Exhibit 99.1 Uroplasty to Host Investor Meeting at Corporate Headquarters March 12th Event to Feature Urologist Perspective on the Use of Uroplasty and Vision-Sciences Product Lines MINNEAPOLIS, March 3, 2015 - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareh |
|
| March 3, 2015 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY INC 8-K 3-3-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2015 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 3, 2015 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Uroplasty to Host Investor Meeting at Corporate Headquarters March 12th Event to Feature Urologist Perspective on the Use of Uroplasty and Vision-Sciences Product Lines MINNEAPOLIS, March 3, 2015 - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunction |
|
| February 23, 2015 |
UPI / Uroplasty Inc DEFM14A - - DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 17, 2015 |
UPI / Uroplasty Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G AMENDMENT FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2015 |
UPI / Uroplasty Inc / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Uroplasty, Inc. (Name of Issuer) Common Stock, $0.01 per share (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2015 |
UPI / Uroplasty Inc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - UROPLASTY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 4)* Uroplasty, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) 12/31/2014 (Date of Event Which Requires Filing of this Statement) C |
|
| February 10, 2015 |
UPI / Uroplasty Inc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - UROPLASTY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 5)* Uroplasty, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) 1/31/2015 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 6, 2015 |
UPI / Uroplasty Inc 10-Q - Quarterly Report - UROPLASTY, INC 10-Q 12-31-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended December 31, 2014 ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to . Commission File No. 001-32632 UROPLASTY, |
|
| February 4, 2015 |
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015 EX-99 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015 Orangeburg, NY – February 4, 2014 – Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products, today announced financial results for the three- and nine-month periods ended December 31, 2014. Third Quarter Fiscal 2015 Hi |
|
| February 4, 2015 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 8-K vsci201502038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2015 VISION-SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-20970 13-3430173 (State or other jurisdiction (Registrati |
|
| January 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2015 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File |
|
| January 27, 2015 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 8-K 1-27-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2015 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File |
|
| January 26, 2015 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC. 425 1-22-2015 Filed by Uroplasty, Inc. pursuant to Rule to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 UROPLASTY, INC. Moderator: Doug Sherk January 22, 2015 3:30 pm CT Operator: Please stand by. Good day everyone and welcome to the Uroplasty Fiscal Third Quarter 2015 Finan |
|
| January 23, 2015 |
UPI / Uroplasty Inc / Amici Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 22, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2015 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File |
|
| January 22, 2015 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Uroplasty Reports Record Revenue in Fiscal Third Quarter ~ Global Urgent PC Sales Up 14.5% ~ ~ Proposed Merger with Vision-Sciences to Expand Innovation in Product Portfolio ~ MINNEAPOLIS, January 22, 2015 - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding d |
|
| January 12, 2015 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY INC 425 1-12-2015 Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 January 2015 Creating a Medical Device Company Positioned for Growth Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statem |
|
| December 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Vision-Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 927912105 (CUSIP Number) Brett Reynolds Senior Vice President, Chief Financial Officer and Corporate Secretary Uroplasty, Inc. 5420 Feltl Road Minnetonka, Minnesota 55343 (9 |
|
| December 23, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 vsci20141222g425.htm Filing under Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Vision-Sciences, Inc. Subject Company: Uroplasty, Inc. SEC File No. of Vision-Sciences 000-20970 UROPLASTY VISION-SCIENCES MERGER ANNOUNCEMENT December 22, 2014 11:00 am ET Operator: Please standby. We’re about to begin. Ladies and g |
|
| December 23, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC. 425 12-22-2014 (CONFERENCE CALL) 425 1 form425.htm UROPLASTY, INC. 425 12-22-2014 (CONFERENCE CALL) Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 UROPLASTY VISION-SCIENCES MERGER ANNOUNCEMENT December 22, 2014 11:00 am ET Operator: Please standby. We’re abou |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 8-K 12-21-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2014 |
EX-10.1 3 ex101.htm EXHIBIT 10.1 Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), is made and entered into as of December 21, 2014, by and between Uroplasty, Inc., a Minnesota corporation (“Uroplasty”), and the undersigned stockholders (each a “Stockholder” and, collectively, the “Stockholders”) of Vision-Sciences, Inc., a Delaware corporation (“Vision-Sciences”) as identifi |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 Dear Valued Customer: We are excited to share with you that Uroplasty has signed a merger agreement with Vision-Sciences to create a medical device company offering innovative tec |
|
| December 22, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 form8k.htm UROPLASTY, INC 8-K 12-21-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 vsci20141222d425.htm Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Vision-Sciences, Inc. Subject Company: Uroplasty, Inc. SEC File No. of Vision-Sciences, Inc.: 000-20970 December 22, 2014 Dear Valued International Sales and Marketing partner: We are excited to share with you that Vision-Sciences has sign |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 December 22, 2014 Dear Valued International Sales and Marketing partner: We are excited to share with you that Uroplasty has signed a merger agreement with Vision-Sciences to crea |
|
| December 22, 2014 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among VISION-SCIENCES, INC., VISOR MERGER SUB LLC, And UROPLASTY, INC. Dated December 21, 2014 Certain schedules to this Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to the SEC upon request. TABLE OF CONTENTS ARTICLE 1 DEFINITIONS |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 425 1 form425.htm UROPLASTY, INC 425 12-21-2014 December 22, 2014 Creating a Medical Device Company Positioned for Growth Draft v12 Filed by Uroplasty, Inc. pursuant to Rule to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 * Forward-Looking Statements This prese |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 vsci20141222c425.htm Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Vision-Sciences, Inc. Subject Company: Uroplasty, Inc. SEC File No. of Vision-Sciences, Inc.: 000-20970 December 22, 2014 Good Morning! We are pleased to share the news of Vision-Sciences signing a merger agreement with Uroplasty to create |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 vsci20141222b425.htm Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Vision-Sciences, Inc. Subject Company: Uroplasty, Inc. SEC File No. of Vision-Sciences, Inc.: 000-20970 December 22, 2014 Dear Valued Customer: We are excited to share with you that Vision-Sciences has signed a merger agreement with Uropla |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 December 2014 Creating a Medical Device Company Positioned for Growth Filed by Uroplasty, Inc. |
|
| December 22, 2014 |
Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), is made and entered into as of December 21, 2014, by and between Uroplasty, Inc., a Minnesota corporation (“Uroplasty”), and the undersigned stockholders (each a “Stockholder” and, collectively, the “Stockholders”) of Vision-Sciences, Inc., a Delaware corporation (“Vision-Sciences”) as identified on Schedule A hereto. A. Concu |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 425 1 form425.htm UROPLASTY, INC 425 12-21-2014 Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 Good Morning! We are excited to bring you the news that Uroplasty and Vision-Sciences have agreed to combine into a new medical dev |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 |
|
| December 22, 2014 |
Exhibit 99.1 NEWS RELEASE Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth All-Stock Combination Creates New Company with Expanded Product Offerings in Urology Conference Call Today at 11:00 AM EST MINNEAPOLIS, MN & ORANGEBURG, NY, December 22, 2014 – Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) entered into a definitive merger |
|
| December 22, 2014 |
EX-99.1 4 ex991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth All-Stock Combination Creates New Company with Expanded Product Offerings in Urology Conference Call Today at 11:00 AM EST MINNEAPOLIS, MN & ORANGEBURG, NY, December 22, 2014 – Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) |
|
| December 22, 2014 |
EX-2.1 2 ex21.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among VISION-SCIENCES, INC., VISOR MERGER SUB LLC, And UROPLASTY, INC. Dated December 21, 2014 Certain schedules to this Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to the SEC upon request. TABLE OF |
|
| December 22, 2014 |
UPI / Uroplasty Inc 425 - Merger Prospectus - UROPLASTY, INC 425 12-21-2014 Filed by Uroplasty, Inc. pursuant to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Uroplasty, Inc. Commission File No. 001-32632 Good Morning! We are pleased to share the news of Uroplasty signing a merger agreement with Vision-Sciences to create a new medical device company offering innovative technologies |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 |
|
| December 22, 2014 |
CGNT / Cogentix Medical, Inc. 425 - Merger Prospectus - FORM 425 vsci20141222425.htm Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Vision-Sciences, Inc. Subject Company: Uroplasty, Inc. SEC File No. of Vision-Sciences, Inc.: 000-20970 December 22, 2014 Good Morning! We are excited to bring you the news that Uroplasty and Vision-Sciences have agreed to combine into a ne |
|
| November 5, 2014 |
UPI / Uroplasty Inc S-3 - - UROPLASTY, INC S-3 11-5-2014 As filed with the Securities and Exchange Commission on November 5, 2014 Registration No. |
|
| November 5, 2014 |
EX-24.1 4 ex241.htm EXHIBIT 24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS: That each person whose signature appears below hereby authorizes and appoints Robert Kill and Brett Reynolds, or any of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and |
|
| October 24, 2014 |
8-K 1 form8k.htm UROPLASTY, INC 8-K 10-22-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other J |
|
| October 24, 2014 |
CONFIDENTIAL SEPARATION AND RELEASE AGREEMENT Exhibit 10.1 CONFIDENTIAL SEPARATION AND RELEASE AGREEMENT This Confidential Separation and Release Agreement (“Agreement”) is made by and between Susan H. Holman (“Holman”) and Uroplasty, Inc., a Minnesota corporation (the “Company”) (together the “Parties”). RECITALS WHEREAS, Holman was employed by the Company until June 21, 2014, pursuant to an Employment Agreement effective as of December 7, 1 |
|
| October 23, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2014 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 |
|
| October 23, 2014 |
Exhibit 99.1 Uroplasty Reports Record Fiscal Second Quarter Revenue ~ Global Urgent PC Sales Up 17.5% ~ ~ Fiscal 2015 Guidance Reaffirmed ~ MINNEAPOLIS, October 23, 2014 - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 second quarter e |
|
| October 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 15, 2014 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty’s Board of Directors Brings 30 Years of Healthcare Delivery System Leadership Experience to Uroplasty MINNEAPOLIS, MN, October 15, 2014 – Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voidin |
|
| October 3, 2014 |
FIRST AMENDMENT EMPLOYMENT AGREEMENT EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”), dated effective as of October 1, 2014 (the “Effective Date”) is entered into by and between Uroplasty, Inc., a Minnesota corporation (the “Company”), and Darin Hammers, a resident of the State of Georgia (the “Employee”) (together the “Parties”). W |
|
| October 3, 2014 |
8-K 1 form8k.htm UROPLASTY, INC. 8-K 10-1-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2014 UROPLASTY, INC. (Exact Name of Registrant as Specified in its Charter) Minnesota 001-32632 41-1719250 (State or other ju |
|
| October 3, 2014 |
UROPLASTY, INC. PERFORMANCE AWARD GRANT NOTICE 2006 EQUITY AND INCENTIVE PLAN EX-10.2 3 ex102.htm EXHIBIT 10.2 Exhibit 10.2 UROPLASTY, INC. PERFORMANCE AWARD GRANT NOTICE 2006 EQUITY AND INCENTIVE PLAN Uroplasty, Inc. (the “Company”) hereby awards to Participant the Performance Award set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Performance Award Grant Notice (the “Grant Notice”), the 2006 Equity and Incentive Pl |
|
| August 22, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2014 UROPLASTY, INC. |
|
| July 24, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2014 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization) (001-32632) 41-1719250 C |
|
| July 24, 2014 |
Exhibit 99 Uroplasty Reports Fiscal First Quarter Results ~ Urgent PC Sales Up 19% in Fiscal First Quarter ~ ~Fiscal 2015 Guidance Reaffirmed~ MINNEAPOLIS, July 24, 2014 - Uroplasty, Inc. |
|
| July 22, 2014 |
UPI / Uroplasty Inc DEF 14A - - UROPLASTY INC DEF 14A 8-19-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| July 8, 2014 |
UPI / Uroplasty Inc PRE 14A - - UROPLASTY INC PRE 14A 8-19-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| June 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 3, 2014 |
FIRST AMENDMENT EMPLOYMENT AGREEMENT EX-10.1 2 ex101.htm EXHIBIT 10.1 EXHIBIT 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”), dated effective as of May 29, 2014 (the “Effective Date”) is entered into by and between Uroplasty, Inc., a Minnesota corporation (the “Company”), and Robert C. Kill, a resident of the State of Minnesota (the “Executive”) (together the “Parties”). W |
|
| June 2, 2014 |
- UROPLASTY, INC SD 12-31-2013 SD 1 formsd.htm UROPLASTY, INC SD 12-31-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 5420 Feltl Road Minnetonka, Minnes |
|
| June 2, 2014 |
Uroplasty, Inc. Conflict Minerals Report For The Year Ended December 31, 2013 Exhibit 1.02 Uroplasty, Inc. Conflict Minerals Report For The Year Ended December 31, 2013 This following report is the Conflict Minerals Report for Uroplasty, Inc. for the year ended December 31, 2013. This report is being filed as an exhibit to Uroplasty’s specialized report on Form SD (“Form SD”) and is intended to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (th |
|
| June 2, 2014 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE Uroplasty Strengthens Board of Directors with Addition of Kevin H. Roche ~Roche Brings Deep Healthcare Industry and Business Strategy Experience~ MINNEAPOLIS, June 2, 2014 /PRNewswire/ - Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voidin |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2014 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 21, 2014 |
SEPARATION AGREEMENT AND RELEASE OF CLAIMS Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Nancy A. Kolb (“Kolb”) and Uroplasty, Inc. (“Uroplasty”) (collectively referred to as the “parties” or individually referred to herein as “party”). WHEREAS, Ms. Kolb has served as Vice President, Global Marketing and Vice President, HealthCare Policy |
|
| May 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 001-32632 41-1719250 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2014 |
Exhibit 99 Uroplasty Reports Fiscal Fourth Quarter and Full Year Results ~ Global Urgent PC Revenue Up 34% in Q4 ~ ~ Total Revenue Up 15% in Q4 ~ MINNEAPOLIS, May 15, 2014 - Uroplasty, Inc. |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2014 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 Com |
|
| February 14, 2014 |
UPI / Uroplasty Inc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - UROPLASTY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 3)* Uroplasty, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) 12/31/2013 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2014 |
UPI / Uroplasty Inc / Manatuck Hill Partners, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2014 |
UPI / Uroplasty Inc / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Uroplasty, Inc. (Name of Issuer) COMMON STOCK, $0.01 PER SHARE (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2014 |
UPI / Uroplasty Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G AMENDMENT FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2014 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 |
|
| January 23, 2014 |
EX-99 2 ex99.htm EXHIBIT 99 Exhibit 99 Uroplasty Reports Record Quarterly Revenue ~ U.S. Urgent PC Sales Up 19% in Fiscal Third Quarter ~ ~ Total Sales Increase by 14% to $6.4 Million~ MINNEAPOLIS, January 23, 2014 - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong fi |
|
| January 9, 2014 |
Regulation FD Disclosure - UROPLASTY, INC 8-K 1-9-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2014 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 |
|
| November 7, 2013 |
As filed with the Securities and Exchange Commission on , 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 41-1719250 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi |
|
| October 24, 2013 |
EX-99 2 ex99.htm EXHIBIT 99 Exhibit 99 Uroplasty Sets New Quarterly Revenue Record During Fiscal Second Quarter 2014 Continued Sequential and Year-over-Year Urgent PC Revenue Growth Reflects Impact of New Sales Strategy and Improved Execution MINNEAPOLIS, October 24, 2013 /PRNewswire/ - Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative propr |
|
| October 24, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 |
|
| September 13, 2013 |
Submission of Matters to a Vote of Security Holders - UROPLASTY INC 8-K 9-12-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2013 UROPLASTY, INC. |
|
| August 19, 2013 |
- UROPLASTY INC DEF A 14A 8-19-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| August 12, 2013 |
EX-99.1 3 ex991.htm EXHIBIT 99.1 Exhibit 99.1 UROPLASTY APPOINTS BRETT REYNOLDS AS CHIEF FINANCIAL OFFICER Former CFO of Synovis Life Technologies Joins Company’s Executive Team MINNEAPOLIS, MN, August 12, 2013 – Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced |
|
| August 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 |
|
| August 12, 2013 |
UROPLASTY, INC. EMPLOYMENT AGREEMENT EXHIBIT 10.1 UROPLASTY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is made and entered into effective the 25th day of July, 2013, between Uroplasty, Inc., a Minnesota corporation, located at 5420 Feltl Road, Minnetonka, Minnesota, 55343 (hereinafter referred to as the "Company") and Brett Reynolds, who resides at 3809 New Brighton Road, Arden Hills, MN 55112 (hereinafter |
|
| July 29, 2013 |
- UROPLASTY INC DEF 14A 9-12-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| July 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 Com |
|
| July 3, 2013 |
Uroplasty Receives NASDAQ Listing Compliance Letter Due to Late Filing of Annual Report on Form 10-K EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Uroplasty Receives NASDAQ Listing Compliance Letter Due to Late Filing of Annual Report on Form 10-K MINNEAPOLIS, MN, July 3, 2013 – Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative products to treat voiding dysfunctions, announced today that it has received a letter from The NASDAQ Stock Market |
|
| June 14, 2013 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Amendment No. 0)* OMB Number 3235-0058 SEC File Number 41-1719250 CUSIP Number 917277 20 4 (Check one): √ Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: March 31, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Rep |
|
| June 14, 2013 |
Uroplasty Announces Delay in Filing Form 10-K Chief Financial Officer on Administrative Leave Exhibit 99 Uroplasty Announces Delay in Filing Form 10-K Chief Financial Officer on Administrative Leave MINNEAPOLIS, MN, June 14, 2013 – Uroplasty, Inc. |
|
| June 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 Co |
|
| May 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (001-32632) 41-1719250 (State or other jurisdiction of incorporation or organization) Co |
|
| May 30, 2013 |
Exhibit 99.1 UROPLASTY REPORTS FISCAL FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS ~U.S. Sales of Urgent® PC increase 11% in Fourth Quarter and 35% for Full Fiscal Year ~ ~Conference call today at 4:30 p.m. ET~ MINNEAPOLIS, MN, May 30, 2013 – Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfu |
|
| April 5, 2013 |
Exhibit 99 UROPLASTY ANNOUNCES CEO RESIGNATION ~David Kaysen Resigns~ ~Independent Director Rob Kill Appointed Interim CEO~ ~Preliminary Revenue Figures for Quarter and Year Ended March 31, 2013~ MINNEAPOLIS, MN, April 5, 2013 – Uroplasty, Inc. |
|
| April 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2013 Uroplasty, Inc. (Exact name of registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organization (001-32632) 41-1719250 Co |
|
| February 14, 2013 |
Amendment No. 2 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Uroplasty, Inc. (Name of Issuer) COMMON STOCK, $0.01 PER SHARE (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2013 |
UPI / Uroplasty Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Uroplasty, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2013 |
UPI / Uroplasty Inc / Manatuck Hill Partners, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2013 |
UPI / Uroplasty Inc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - UROPLASTY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2)* Uroplasty, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) 12/31/2012 (Date of Event Which Requires Filing of this Statement) C |
|
| January 31, 2013 |
Uroplasty, Inc. 5420 Feltl Road Minnetonka, MN 55343 USA Toll free 866 258 2182 Fax 952 426 6199 www uroplasty.com January 31, 2013 VIA EDGAR and FACSIMILE Securities and Exchange Commission Attn: Kevin L. Vaughn Accounting Branch Chief Washington, DC 20549 Re: Uroplasty, Inc. Form 10-K for the Fiscal Year Ended March 31, 2012 Filed May 24, 2012 File No. 001-32632 Dear Mr. Vaughn: This letter is i |
|
| September 17, 2012 |
Submission of Matters to a Vote of Security Holders - UROPLASTY INC 8-K 9-13-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2012 UROPLASTY, INC. |
|
| August 23, 2012 |
UPI / Uroplasty Inc / Ayer Capital Management, LP - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* UROPLASTY INC (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) May 17, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| July 27, 2012 |
- UROPLASTY INC DEF 14A 9-13-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| May 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UROPLASTY, INC. (Exact name of registrant as specified in its charter) Minnesota 41-1719250 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5420 Feltl Road Minnetonka, Minnesota, 55343 (Address of principal exec |
|
| April 4, 2012 |
UPI / Uroplasty Inc / Ayer Capital Management, LP - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* UROPLASTY INC (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 20, 2012 |
UPI / Uroplasty Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Uroplasty, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 917277204 (CUSIP Number) March 09, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 14, 2012 |
UPI / Uroplasty Inc / Manatuck Hill Partners, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2012 |
UPI / Uroplasty Inc / Visium Asset Management, LP - AMENDMENT NO.1 Passive Investment SC 13G/A 1 d299436dsc13ga.htm AMENDMENT NO.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Uroplasty, Inc. (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 917277204 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 31, 2012 |
UPI / Uroplasty Inc / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - UROPLASTY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1)* Uroplasty, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917277204 (CUSIP Number) 12/31/2011 (Date of Event Which Requires Filing of this Statement) C |
